ProfileGDS5678 / 1440911_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 43% 43% 44% 60% 42% 41% 43% 43% 44% 43% 42% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0289243
GSM967853U87-EV human glioblastoma xenograft - Control 23.0035543
GSM967854U87-EV human glioblastoma xenograft - Control 33.0068943
GSM967855U87-EV human glioblastoma xenograft - Control 42.9610944
GSM967856U87-EV human glioblastoma xenograft - Control 53.5347660
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0494842
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0131641
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9868943
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9833443
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0006244
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9960643
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9462742
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9989643
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.986543